1 unchanged sentence
Securities Trading Plans of Directors and Executive Officers
−Removed: During our last fiscal quarter, none of our directors or officers, as defined in Rule 16a-1(f), adopted a “Rule 10b5-1 trading arrangement” or a “ non-Rule 10b5-1 trading arrangement ,” as defined in Regulation S-K Item 408.
−Removed: On September 28, 2024 , Neil Desai , a director and our former Executive Chairman , terminated a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c), which had been originally adopted on September 20, 2021, as replaced on December 1, 2022.
+Added: During our last fiscal quarter, none of our directors or officers, as defined in Rule 16a-1(f), adopted and/or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408.
The exhibits listed on the Exhibit Index immediately preceding such exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report.
−Removed: 3.1 Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on August 27, 2021).
−Removed: 3.2 Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on December 7, 2022).
−Removed: 10.1# Form of Retention Bonus Letters with executive officers (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-38560) filed with the SEC on September 19, 2024).
−Removed: 10.2*+ Amendment No.3 to the Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product, effective as of July 31, 2024, by and between Aadi Bioscience, Inc.
−Removed: and Fresenius Kabi, LLC .
−Removed: 10.3*# Transition Agreement and Release by and between Neil Desai and Aadi Bioscience, Inc., dated October 16, 2024 .
−Removed: 10.4*# Transition Agreement and Release by and between Loretta Itri and Aadi Bioscience, Inc., dated September 16, 2024 .
+Added: 3.1 Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No.
+Added: 001-38560) filed with the SEC on March 18 , 202 5 ).
+Added: 3.2 Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.
+Added: 2 to the Registrant’s Current Report on Form 8-K (File No.
+Added: 001-38560) filed with the SEC on March 18 , 202 5 ).
+Added: 10.1* Amendment #1 to Intellectual Property License Agreement, dated April 7, 2025, between the Registrant and WuXi Biologics (Shanghai FX) Co., Ltd.
+Added: 10.2* Amendment No.
+Added: 1 to Sales Agreement by and between the Company and TD Securities (USA) LLC (as successor to Cowen and Company, LLC) dated April 25, 2025.
+Added: 10.3 Registration Rights Agreement, by and among the Company and the purchasers thereto, dated March 4, 2025 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No.
+Added: 001-38560) filed with the SEC on March 4, 2025).
+Added: 10.4# Amended and Restated 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K (File No.
+Added: 001-38560) filed with the SEC on March 4, 2025).
+Added: 10.5# Executive Employment Agreement, effective as of February 18, 2025, by and between the Company and David Dornan, Ph.D (incorporated by reference to Exhibit 10.26 to the Registrant’s Annual Report on Form 10-K (File No.
+Added: 001-38560) filed with the SEC on March 28, 2025.
31.1* Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
10 unchanged sentences
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
−Removed: 104 Cover Page Interactive Data File (embedded with the Inline XBRL document.)
+Added: 104 Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)
* Filed herewith.
+Added: # Indicates a management contract or any compensatory plan, contract or arrangement.
** The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to be furnished with this Quarterly Report on Form 10-Q and will not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.
−Removed: + Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
−Removed: # Indicates a management contract or compensatory plan, contract or arrangement.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: AADI BIOSCIENCE, INC.
−Removed: November 6, 2024
+Added: WHITEHAWK THERAPEUTICS, INC.
/s/ Scott Giacobello
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.